Editas Medicine (EDIT) announced CFO Erick Lucera is stepping down to pursue an external opportunity, effective March 28. Current senior VP of finance Amy Parison will succeed Lucera as CFO. Parison has more than 18 years of financial, accounting, and business development experience in life sciences. During her time at Editas, she has served in multiple roles of increasing responsibilities including senior VP, finance, and VP and corporate controller.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
- Biotech Alert: Searches spiking for these stocks today
- Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
- Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
- Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability